You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Immunomodulation with regulatory T cells and Fas-ligand ameliorate established inflammatory colitis

https://doi.org/10.1136/gutjnl-2012-304432

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors All authors contributed to production of the data and preparation of the letter.

    • Funding This work was supported by grants from the Frankel Trust for Experimental Bone Marrow Transplantation.

    • Competing interests The SA-FasL protein and ProtEx technology described in this manuscript are licenced from UofL by ApoImmune, Inc, Louisville, KY, in which ESY has significant equity interest in the Company. The other authors disclosed no potential competing interests.

    • Provenance and peer review Not commissioned; internally peer reviewed.